{"search_session":{},"preferences":{"l":"fr","queryLanguage":"fr"},"patentId":"US_9506039_B2","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"066-106-973-849-431","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8878,"type":"PATENT","title":"Kyoto University Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":10470,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8212,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately = \"Kyoto University\", \"Kyoto Univ\", \" Univ Kyoto\", \" University Kyoto\", \"Kyot* Univ*\", \"Univ* Kyot*\".
Select more for variants
Add to collection
Select the collection expanded by simple families
Add to collection
Search Applicants and Owners separately = \"Kyoto University\", \"Kyoto Univ\", \" Univ Kyoto\", \" University Kyoto\", \"Kyot* Univ*\", \"Univ* Kyot*\".
Select more for variants
Add to collection
Select the collection expanded by simple families
Add to collection
wherein the nuclear reprogramming substance(s) comprises a nucleic acid vector encoding Oct3/4 and optionally comprises a nucleic acid vector(s) encoding one or more substances selected from the group consisting of Sox2, Klf4, c-Myc, Lin28 and Nanog."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 1, wherein the AKT family members are constitutively active forms."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 1, wherein the AKT family members are selected from the group consisting of AKT1, AKT2 and AKT3."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 2, wherein the AKT family members constitutively activate signal transduction pathway of mTOR pathway."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 1, further comprising contacting one or more factors selected from the group consisting of p53 inhibitor, GLIS family members, and nucleic acids that encode the same with the somatic cell."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 1, wherein the nuclear reprogramming substances comprise a nucleic acid vector(s) encoding Oct3/4, Klf4 and Sox2."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 1, wherein the nuclear reprogramming substances comprise a nucleic acid vector(s) encoding Oct3/4, Klf4, Sox2, as well as c-Myc or L-Myc and/or Nanog and/or Lin28 or Lin28B."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["A method of improving the efficiency of establishment of a reprogrammed cell, comprising contacting a somatic cell with (a) a nuclear reprogramming substance(s) and (b) a nucleic acid vector(s) encoding one or more AKT family members, thereby improving the efficiency of establishment of reprogrammed cells as compared to the establishment of reprogrammed cells established without contacting the somatic cell with (b),\n
wherein the nuclear reprogramming substance(s) comprises a nucleic acid vector encoding Oct3/4 and optionally comprises a nucleic acid vector(s) encoding one or more substances selected from the group consisting of Sox2, Klf4, c-Myc, Lin28 and Nanog, and\n
wherein the reprogrammed cell is in a more undifferentiated state than the somatic cell so as to form an ES-like colony."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 8, wherein the AKT family members are constitutively active forms."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 8, wherein the AKT family members are selected from the group consisting of AKT1, AKT2 and AKT3."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 9, wherein the AKT family members constitutively activate signal transduction pathway of mTOR pathway."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 8, further comprising contacting one or more factors selected from the group consisting of p53 inhibitor, GLIS family members, and nucleic acids that encode the same with the somatic cell."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 8, wherein the nuclear reprogramming substances comprise a nucleic acid vector(s) encoding Oct3/4, Klf4 and Sox2."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 8, wherein the nuclear reprogramming substances comprise a nucleic acid vector(s) encoding Oct3/4, Klf4, Sox2, as well as c-Myc or L-Myc and/or Nanog and/or Lin28 or Lin28B."],"number":14,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}